DeepMed Research

DANA-FARBER CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1947-01-01

Employees: -

Market Cap: -

Website: http://www.dana-farber.org/

Clinical Trials

ABEMA Alone or in COMBO With MK-6482

Phase 1

Completed

Conditions: Clear Cell Renal Cell Carcinoma

Interventions: Drug: Abemaciclib
Drug: MK-6482

First Posted Date: 2020-11-13

Last Posted Date: 2025-04-11

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 11

Registration Number: NCT04627064

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas

Phase 2

Recruiting

Conditions: Salivary Gland Cancer
HER2 Gene Mutation

Interventions: Drug: Ado-trastuzumab (T) emtansine (T-DM1)
Radiation: Standard of Care Radiotherapy
Drug: Standard of Care Chemotherapy

First Posted Date: 2020-11-06

Last Posted Date: 2025-02-18

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 55

Registration Number: NCT04620187

Locations: 🇺🇸
David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Memorial Sloan Kettering Commack, Commack, New York, United States
🇺🇸
Memorial Sloan Kettering Nassau, Uniondale, New York, United States

and more 9 locations

Axi-cel in CNS Lymphoma

Phase 1

Active, not recruiting

Conditions: Lymphoma Cns
Lymphoma

Interventions: Drug: Fludarabine
Drug: Cyclophosphamide
Biological: Axicabtagene Ciloleucel

First Posted Date: 2020-10-29

Last Posted Date: 2025-01-29

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 18

Registration Number: NCT04608487

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

Niraparib + Dostarlimab In BRCA Mutated Breast Cancer

Phase 2

Active, not recruiting

Conditions: Germline BRCA2 Gene Mutation
Germline BRCA1 Gene Mutation
Deleterious PALB2 Gene Mutation
Stage I Breast Cancer
Stage II Breast Cancer
Breast Cancer
HER2-negative Breast Cancer
Stage III Breast Cancer

Interventions: Drug: Niraparib
Drug: Dostarlimab

First Posted Date: 2020-10-12

Last Posted Date: 2025-04-27

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 62

Registration Number: NCT04584255

Locations: 🇺🇸
Yale University Cancer Center, New Haven, Connecticut, United States
🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

and more 5 locations

Copanlisib Plus Venetoclax in R/R DLBCL

Phase 1

Active, not recruiting

Conditions: Relapsed Diffuse Large B-Cell Lymphoma
Refractory Diffuse Large B-Cell Lymphoma
Diffuse Large B Cell Lymphoma

Interventions: Drug: Copanlisib
Drug: Venetoclax

First Posted Date: 2020-10-01

Last Posted Date: 2024-12-20

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 48

Registration Number: NCT04572763

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
City of Hope Cancer Center, Duarte, California, United States
🇺🇸
Siteman Cancer Center at Washington University, Saint Louis, Missouri, United States

A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer

Phase 2

Recruiting

Conditions: Micrometastasis Breast Cancer
Breast Cancer
Hormone Receptor Positive Breast Cancer
HER2-positive Breast Cancer
Invasive Carcinoma of the Breast
Node Negative Breast Cancer

Interventions: Combination Product: Pertuzumab+TRASTUZUMAB
Drug: ADJUVANT ENDOCRINE THERAPY

First Posted Date: 2020-09-30

Last Posted Date: 2024-10-01

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 375

Registration Number: NCT04569747

Locations: 🇺🇸
UNC Rex Cancer Center, Raleigh, North Carolina, United States
🇺🇸
Stamford Hospital, Stamford, Connecticut, United States
🇺🇸
Winship Cancer Institute at Emory University Hospital Midtown, Atlanta, Georgia, United States

and more 25 locations

My Mindful Moments: A Mindfulness Meditation and Digital Art Activity

Not Applicable

Completed

Conditions: Mindfulness
Meditation

Interventions: Other: Mindfulness intervention

First Posted Date: 2020-09-21

Last Posted Date: 2022-08-25

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 16

Registration Number: NCT04557033

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Jump: MR Simulation For Radiation Therapy Master Protocol

Not Applicable

Recruiting

Conditions: Liver Cancer
Prostate Cancer
Recurrent Adenocarcinoma
Head and Neck Cancer

Interventions: Device: MRI Simulator
Radiation: Radiation Therapy

First Posted Date: 2020-09-11

Last Posted Date: 2023-11-14

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 86

Registration Number: NCT04545957

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Brigham and Women Hospital, Boston, Massachusetts, United States

Li-Fraumeni & TP53 (LiFT UP): Understanding and Progress

Recruiting

Conditions: Li-Fraumeni Syndrome
Clonal Hematopoiesis
Hereditary Cancer Syndrome
TP53 Gene Mutation
Mosaicism

Interventions: Genetic: Data and Specimen Collection

First Posted Date: 2020-09-09

Last Posted Date: 2024-03-20

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 1500

Registration Number: NCT04541654

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸
Judy E. Garber, Boston, Massachusetts, United States

REVITALIZE: A Telehealth Intervention for Women With Advanced Ovarian Cancer and PARP Inhibitor-Related Fatigue

Not Applicable

Completed

Conditions: Fatigue
Ovarian Cancer
Coping Skills
Coping Behavior

Interventions: Behavioral: REVITALIZE ACT Intervention
Behavioral: Enhanced Usual Care (EOC)

First Posted Date: 2020-08-25

Last Posted Date: 2024-11-15

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 49

Registration Number: NCT04525183

Locations: 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy